{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:24Z","timestamp":1790610804755,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ripretinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumors (GISTs) who have previously received treatment with at least three kinase inhibitors. The objective of this study was to evaluate adverse events(AEs) associated with ripretinib using data from the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individual case safety reports (ICSRs) related to of ripretinib from 2020 Q2 to 2024 Q2 were extracted from the FAERS database. This study used the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) for disproportionality analysis. In addition, this research also performed a descriptive analysis of the time-to-onset (TTO) of AEs related to ripretinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3,513 ICSRs with ripretinib as the primary suspect (PS) were retrieved from the FAERS database. At the preferred term(PT) level, this study detected 116 positive AEs. Common AEs included alopecia, constipation, muscle spasms, dry skin, decreased appetite. Notably, unexpected AEs such as pleural mass, blood magnesium abnormal, blood potassium abnormal, hepatic lesion, and liver abscess were also observed. The median time to onset of ripretinib-related AEs was 102 days (29\u2013254 days), with the majority of AEs occurring during the first month of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified some known AEs associated with ripretinib and discovered unexpected AEs, providing preliminary insights into its safety in the real world. This information is valuable for clinical monitoring and the safe use of ripretinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1481114","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:29:33Z","timestamp":1740536973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Ye","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qineng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunlin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/cancers15061851","article-title":"Neuropsychiatric adverse drug reactions with tyrosine kinase inhibitors in gastrointestinal stromal tumors: an analysis from the European spontaneous adverse event reporting system","volume":"15","author":"Barbieri","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/s1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00228-022-03298-y","article-title":"Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?","volume":"78","author":"De Francia","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40265-020-01348-2","article-title":"Ripretinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s40265-022-01794-0","article-title":"Ripretinib: a review in gastrointestinal stromal tumours as fourth-or later-line of therapy","volume":"82","author":"Fung","year":"2022","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1535-7163.Mct-20-0824","article-title":"Ripretinib and MEK inhibitors synergize to induce apoptosis in preclinical models of GIST and systemic mastocytosis","volume":"20","author":"Gupta","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000515219","article-title":"Management of chronic diarrhea in primary care: the gastroenterologists' advice","volume":"39","author":"Hammer","year":"2021","journal-title":"Dig. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3390\/ijms24032312","article-title":"Cabozantinib, vandetanib, pralsetinib and selpercatinib as treatment for progressed medullary thyroid cancer with a main focus on hypertension as adverse effect","volume":"24","author":"H\u00f8jer Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"100520","DOI":"10.1016\/j.esmoop.2022.100520","article-title":"Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma","volume":"7","author":"Janku","year":"2022","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/s1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1420478","DOI":"10.3389\/fphar.2024.1420478","article-title":"Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023","volume":"15","author":"Lin","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J. Neurooncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fphar.2017.00367","article-title":"Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis","volume":"8","author":"Paech","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.annonc.2021.05.162","article-title":"P-107 Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib","volume":"32","author":"Patel","year":"2021","journal-title":"Ann. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfaa174","article-title":"Tyrosine kinase inhibitor-induced hypertension-marker of anti-tumour treatment efficacy or cardiovascular risk factor?","volume":"14","author":"Ptinopoulou","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/mcc.0000000000000188","article-title":"Diarrhoea in the critically ill","volume":"21","author":"Reintam Blaser","year":"2015","journal-title":"Curr. Opin. Crit. Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1186\/s12885-022-10379-9","article-title":"Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial","volume":"22","author":"Sch\u00f6ffski","year":"2022","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ceg.S351839","article-title":"Emerging data on the safety and efficacy of ripretinib for the treatment of gastrointestinal stromal tumors","volume":"16","author":"Thirasastr","year":"2023","journal-title":"Clin. Exp. Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S1120","DOI":"10.1016\/j.annonc.2021.08.870","article-title":"1540P Ripretinib as \u22654th-line treatment in patients with advanced gastrointestinal stromal tumor: long-term update from the phase III INVICTUS study","volume":"32","author":"Von Mehren","year":"2021","journal-title":"Ann. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Wang","year":"2024","journal-title":"Andrology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17562848211008177","DOI":"10.1177\/17562848211008177","article-title":"Ripretinib for the treatment of advanced gastrointestinal stromal tumor","volume":"14","author":"Zalcberg","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14740338.2023.2193392","article-title":"Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event reporting system database","volume":"22","author":"Zhang","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1481114\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:29:35Z","timestamp":1740536975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1481114\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":28,"alternative-id":["10.3389\/fphar.2025.1481114"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1481114","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"article-number":"1481114"}}